BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 21122666)

  • 1. Report of simultaneous acute pancreatitis and acute hepatitis in a patient taking ezetimibe/simvastatin.
    Van Woerkom RC; Adler DG
    J Clin Lipidol; 2010; 4(4):314-5. PubMed ID: 21122666
    [No Abstract]   [Full Text] [Related]  

  • 2. A case of acute pancreatitis possibly associated with combined salicylate and simvastatin treatment.
    Antonopoulos S; Mikros S; Kokkoris S; Protopsaltis J; Filioti K; Karamanolis D; Giannoulis G
    JOP; 2005 May; 6(3):264-8. PubMed ID: 15883478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simvastatin + ezetimibe: a combination with no proven advantages.
    Prescrire Int; 2007 Apr; 16(88):67. PubMed ID: 17460829
    [No Abstract]   [Full Text] [Related]  

  • 4. Ezetimibe + simvastatin (Merck/Schering-Plough).
    Flores NA
    Curr Opin Investig Drugs; 2004 Sep; 5(9):984-92. PubMed ID: 15503655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safe use of ezetimibe plus simvastatin in high-risk vascular patients (with chronic kidney disease and PAD).
    Aalbers J
    Cardiovasc J Afr; 2011; 22(4):227-8. PubMed ID: 21881698
    [No Abstract]   [Full Text] [Related]  

  • 6. [On the current debate on lowering LDL cholesterol with ezetimibe].
    Breuer HW
    Dtsch Med Wochenschr; 2010 Nov; 135(44):2201; author reply 2202. PubMed ID: 20979008
    [No Abstract]   [Full Text] [Related]  

  • 7. Tolerability and effects on lipids of ezetimibe coadministered with pravastatin or simvastatin for twelve months: results from two open-label extension studies in hypercholesterolemic patients.
    Strony J; Hoffman R; Hanson M; Veltri E
    Clin Ther; 2008 Dec; 30(12):2280-97. PubMed ID: 19167588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. After the failure of ENHANCEd cholesterol lowering in familial hypercholesterolemia, SEAS of problems with ezetimibe.
    Mascitelli L; Ravnskov U; Pezzetta F; Goldstein MR
    Angiology; 2009; 60(1):127-8; author reply 129-30. PubMed ID: 19049996
    [No Abstract]   [Full Text] [Related]  

  • 9. Ezetimibe/simvastatin.
    Montecucco F; Quercioli A; Mach F
    Expert Opin Drug Saf; 2009 Nov; 8(6):715-25. PubMed ID: 19968571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia.
    Bays HE; Ose L; Fraser N; Tribble DL; Quinto K; Reyes R; Johnson-Levonas AO; Sapre A; Donahue SR;
    Clin Ther; 2004 Nov; 26(11):1758-73. PubMed ID: 15639688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ezetimibe and recent clinical trials: a look on the bright side.
    Ahmed MH
    Expert Opin Drug Saf; 2010 Jul; 9(4):511-4. PubMed ID: 20377476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ezetimibe and cancer--an uncertain association.
    Drazen JM; D'Agostino RB; Ware JH; Morrissey S; Curfman GD
    N Engl J Med; 2008 Sep; 359(13):1398-9. PubMed ID: 18765434
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials.
    Feldman T; Davidson M; Shah A; Maccubbin D; Meehan A; Zakson M; Tribble D; Veltri E; Mitchel Y
    Clin Ther; 2006 Jun; 28(6):849-59. PubMed ID: 16860168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Premature release of data from clinical trials of ezetimibe.
    Califf RM; Harrington RA; Blazing MA
    N Engl J Med; 2009 Aug; 361(7):712-7. PubMed ID: 19675335
    [No Abstract]   [Full Text] [Related]  

  • 15. Drug-induced acute autoimmune hepatitis during combination therapy with atorvastatin and ezetimibe.
    van Heyningen C
    Ann Clin Biochem; 2005 Sep; 42(Pt 5):402-4. PubMed ID: 16168199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In brief: Ezetimibe/simvastatin (Vytorin) in chronic kidney disease.
    Med Lett Drugs Ther; 2012 Jan; 54(1381):4. PubMed ID: 22233589
    [No Abstract]   [Full Text] [Related]  

  • 17. [How sure is the combined lipid lowering?].
    Schäfer J
    MMW Fortschr Med; 2005 Jan; 147(1-2):56. PubMed ID: 15704576
    [No Abstract]   [Full Text] [Related]  

  • 18. Long-term safety and, tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: a multicenter, randomized, double-blind, placebo-controlled, 48-week extension study.
    Masana L; Mata P; Gagné C; Sirah W; Cho M; Johnson-Levonas AO; Meehan A; Troxell JK; Gumbiner B;
    Clin Ther; 2005 Feb; 27(2):174-84. PubMed ID: 15811480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.
    Rossebø AB; Pedersen TR; Boman K; Brudi P; Chambers JB; Egstrup K; Gerdts E; Gohlke-Bärwolf C; Holme I; Kesäniemi YA; Malbecq W; Nienaber CA; Ray S; Skjaerpe T; Wachtell K; Willenheimer R;
    N Engl J Med; 2008 Sep; 359(13):1343-56. PubMed ID: 18765433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LDL-C goal attainment with the addition of ezetimibe to ongoing simvastatin treatment in coronary heart disease patients with hypercholesterolemia.
    Brohet C; Banai S; Alings AM; Massaad R; Davies MJ; Allen C
    Curr Med Res Opin; 2005 Apr; 21(4):571-8. PubMed ID: 15899106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.